Eva Kimby
伊娃·金比
MD, PhD
Professor Emerita of Hematology血液学荣誉教授
👥Biography 个人简介
Professor Eva Kimby is a pioneering Scandinavian hematologist who co-developed the Nordic MCL protocol — one of the most effective intensive induction regimens for mantle cell lymphoma internationally. The Nordic MCL2 and MCL3 trials, which she co-led through the Nordic Lymphoma Group, demonstrated that alternating maxi-CHOP and high-dose cytarabine followed by autologous stem cell transplantation yielded 10-year overall survival rates exceeding 40% in MCL, a previously chemotherapy-resistant disease. Her work helped establish the rationale for cytarabine incorporation into MCL induction globally. She also made major contributions to understanding watchful waiting strategies in indolent lymphomas.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Nordic MCL Protocol Development
Co-developed and led the Nordic MCL2 trial comparing alternating maxi-CHOP/high-dose cytarabine induction followed by auto-SCT versus CHOP, establishing the superiority of the cytarabine-containing Nordic regimen and making it a global reference standard for intensive MCL therapy in younger patients.
Long-Term Outcomes in MCL with Auto-SCT
Published landmark long-term follow-up data from the Nordic MCL trials showing 10- and 12-year overall survival rates that redefined the natural history of MCL when treated with intensive protocols, challenging the previously accepted notion of uniformly poor outcomes.
Watch-and-Wait in Asymptomatic Follicular Lymphoma
Led Swedish studies validating the watch-and-wait approach for asymptomatic low-burden follicular lymphoma, confirming that deferred treatment does not compromise overall survival compared to immediate chemotherapy and reducing unnecessary treatment toxicity.
Representative Works 代表性著作
Superior survival for mantle cell lymphoma (MCL) patients treated with the Nordic MCL2 protocol compared with R-CHOP: outcomes after a median of 11 years
Annals of Oncology (2014)
Long-term follow-up data demonstrating the lasting survival benefit of the Nordic MCL protocol versus standard CHOP-based induction.
High-dose cytarabine is a critical component of the Nordic Lymphoma Group MCL regimen: randomized MCL1 trial analysis
Journal of Clinical Oncology (2012)
Randomized evidence establishing the necessity of cytarabine in the Nordic MCL induction backbone.
Deferred therapy is safe in patients with asymptomatic follicular lymphoma: a prospective observational study
Blood (2009)
Prospective study validating that observation without immediate treatment is appropriate for asymptomatic low-tumor-burden follicular lymphoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 伊娃·金比 的研究动态
Follow Eva Kimby's research updates
留下邮箱，当我们发布与 Eva Kimby（Karolinska University Hospital / Karolinska Institutet）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment